Peroxisome proliferator-activated receptorgamma (PPARγ) is down regulated in trophoblast cells of gestational diabetes mellitus (GDM) and in trophoblast tumour cells BeWo in vitro after stimulation with PPARγ agonists

Journal of Perinatal Medicine

Volumn 42, Issue 2, 2014, Pages 179-187

  Knabl, Julia ^a   Huttenbrenner, Rebecca ^a   Hutter, Stefan ^a   Gunthner Biller, Maria ^a   Vrekoussis, Thomas ^a   Karl, Katrin ^a   Friese, Klaus ^a,b   Kainer, Franz ^a   Jeschke, Udo ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Arachidonic acid; BeWo cells; Gestational diabetes mellitus; PPAR ; Prostaglandin; Trophoblast cells

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ARACHIDONIC ACID; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PLACENTA; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNCYTIOTROPHOBLAST; TROPHOBLAST; TROPHOBLASTIC TUMOR; AGONISTS; CASE CONTROL STUDY; METABOLISM; PREGNANCY; TUMOR CELL LINE;

ADULT; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DIABETES, GESTATIONAL; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PPAR GAMMA; PREGNANCY; TROPHOBLASTIC NEOPLASMS; TROPHOBLASTS;

EID: 84896958962     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/jpm-2013-0039     Document Type: Article

References (51)

1. AlSaleh A, Sanders TA, O'Dell SD. Effect of interaction between PPARG, PPARA and ADIPOQ gene variants and dietary fatty acids on plasma lipid profile and adiponectin concentration in a large intervention study. Proc Nutr Soc. 2012;71:141-53.
2. Arck P, Toth B, Pestka A, Jeschke U. Nuclear receptors of the peroxisome proliferator-activated receptor (PPAR) family in gestational diabetes: from animal models to clinical trials. Biol Reprod. 2010;83:168-76.
3. Barlic J, Murphy PM. An oxidized lipid-peroxisome proliferatoractivated receptor gamma-chemokine pathway in the regulation of macrophage-vascular smooth muscle cell adhesion. Trends Cardiovasc Med. 2007;17:269-74.
4. Barnes-Powell LL. Infants of diabetic mothers: the effects of hyperglycemia on the fetus and neonate. Neonatal Netw. 2007;26:283-90.
5. Baumann MU, Deborde S, Illsley NP. Placental glucose transfer and fetal growth. Endocrine. 2002;19:13-22.
6. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-35.
7. Bitsanis D, Ghebremeskel K, Moodley T, Crawford MA, Djahanbakhch O. Gestational diabetes mellitus enhances arachidonic and docosahexaenoic acids in placental phospholipids. Lipids. 2006;41:341-6.
8. Bomba-Opon D, Wielgos M, Szymanska M, Bablok L. Effects of free fatty acids on the course of gestational diabetes mellitus. Neuro Endocrinol Lett. 2006;27:277-80.
9. Capobianco E, Jawerbaum A, Romanini MC, White V, Pustovrh C, Higa R, et al. 15-Deoxy-delta12, 14-prostaglandin J2 and peroxisome proliferator-activated receptor gamma (PPARgamma) levels in term placental tissues from control and diabetic rats: modulatory effects of a PPARgamma agonist on nitridergic and lipid placental metabolism. Reprod Fertil Dev. 2005;17:423-33.
10. Capobianco E, White V, Higa R, Martinez N, Jawerbaum A. Effects of natural ligands of PPARgamma on lipid metabolism in placental tissues from healthy and diabetic rats. Mol Hum Reprod. 2008;14:491-9.
11. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol. 1982;144:768-73.
12. Chen X, Scholl TO, Leskiw M, Savaille J, Stein TP. Differences in maternal circulating fatty acid composition and dietary fat intake in women with gestational diabetes mellitus or mild gestational hyperglycemia. Diabetes Care. 2010;33:2049-54.
13. Ditsch N, Vrekoussis T, Lenhard M, Ruhl I, Gallwas J, Weissenbacher T, et al. Retinoid X receptor alpha (RXRalpha) and peroxisome proliferator-activated receptor gamma (PPARgamma) expression in breast cancer: an immunohistochemical study. In Vivo. 2012;26:87-92.
14. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803-12.
15. Fournier T, Guibourdenche J, Handschuh K, Tsatsaris V, Rauwel B, Davrinche C, et al. PPARgamma and human trophoblast differentiation. J Reprod Immunol. 2011;90:41-9.
16. Fournier T, Handschuh K, Tsatsaris V, Evain-Brion D. Involvement of PPARgamma in human trophoblast invasion. Placenta. 2007;28(Suppl A):S76-81.
17. Gil-Sanchez A, Demmelmair H, Parrilla JJ, Koletzko B, Larque E. Mechanisms involved in the selective transfer of long chain polyunsaturated fatty acids to the fetus. Front Genet. 2011;2:57.
18. Grummer R, Hohn HP, Mareel MM, Denker HW. Adhesion and invasion of three human choriocarcinoma cell lines into human endometrium in a three-dimensional organ culture system. Placenta. 1994;15:411-29.
19. Haigh T, Chen C, Jones CJ, Aplin JD. Studies of mesenchymal cells from 1st trimester human placenta: expression of cytokeratin outside the trophoblast lineage. Placenta. 1999;20:615-25.
20. Hanebutt FL, Demmelmair H, Schiessl B, Larque E, Koletzko B. Long-chain polyunsaturated fatty acid (LC-PUFA) transfer across the placenta. Clin Nutr. 2008;27:685-93.
21. Hirano T, Higuchi T, Katsuragawa H, Inoue T, Kataoka N, Park KR, et al. CD9 is involved in invasion of human trophoblast-like choriocarcinoma cell line, BeWo cells. Mol Hum Reprod. 1999;5:168-74.
22. Holdsworth-Carson SJ, Lim R, Mitton A, Whitehead C, Rice GE, Permezel M, et al. Peroxisome proliferator-activated receptors are altered in pathologies of the human placenta: gestational diabetes mellitus, intrauterine growth restriction and preeclampsia. Placenta. 2010;31:222-9.
23. Jansson T, Wennergren M, Illsley NP. Glucose transporter protein expression in human placenta throughout gestation and in intrauterine growth retardation. J Clin Endocrinol Metab. 1993;77:1554-62.
24. Jawerbaum A, Capobianco E, Pustovrh C, White V, Baier M, Salzberg S, et al. Influence of peroxisome proliferatoractivated receptor gamma activation by its endogenous ligand 15-deoxy delta12,14 prostaglandin J2 on nitric oxide production in term placental tissues from diabetic women. Mol Hum Reprod. 2004;10:671-6.
25. Kersten S, Wahli W. Peroxisome proliferator activated receptor agonists. EXS. 2000;89:141-51.
26. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferatoractivated receptors alpha and gamma. Proc Natl Acad Sci USA. 1997;94:4318-23.
27. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell. 1999;4:597-609.
28. Kuhn DC, Botti JJ, Cherouny PH, Demers LM. Eicosanoid production and transfer in the placenta of the diabetic pregnancy. Prostaglandins. 1990;40:205-15.
29. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology. 2003;144:2201-7.
30. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953-6.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-8.
32. Maes M, Mihaylova I, Kubera M, Bosmans E. Why fish oils may not always be adequate treatments for depression or other inflammatory illnesses: docosahexaenoic acid, an omega-3 polyunsaturated fatty acid, induces a Th-1-like immune response. Neuro Endocrinol Lett. 2007;28:875-80.
33. Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care. 2007;30(Suppl 2):S251-60.
34. Min Y, Nam JH, Ghebremeskel K, Kim A, Crawford M. A distinctive fatty acid profile in circulating lipids of Korean gestational diabetics: a pilot study. Diabetes Res Clin Pract. 2006;73:178-83.
35. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998;93:229-40.
36. O'Moore-Sullivan TM, Prins JB. Thiazolidinediones and type 2 diabetes: new drugs for an old disease. Med J Aust. 2002;176:381-6.
37. Orendi K, Gauster M, Moser G, Meiri H, Huppertz B. The choriocarcinoma cell line BeWo: syncytial fusion and expression of syncytium-specific proteins. Reproduction. 2010;140:759-66.
38. Ortega-Senovilla H, Schaefer-Graf U, Meitzner K, Abou-Dakn M, Graf K, Kintscher U, et al. Gestational diabetes mellitus causes changes in the concentrations of adipocyte fatty acid-binding protein and other adipocytokines in cord blood. Diabetes Care. 2011;34:2061-6.
39. Powell TL, Jansson T, Illsley NP, Wennergren M, Korotkova M, Strandvik B. Composition and permeability of syncytiotrophoblast plasma membranes in pregnancies complicated by intrauterine growth restriction. Biochim Biophys Acta. 1999;1420:86-94.
40. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. [In German]. Pathologe. 1987;8:138-40.
41. Ricote M, Huang JT, Welch JS, Glass CK. The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function. J Leukoc Biol. 1999;66:733-9.
42. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011;57:e1-47.
43. Schaefer-Graf UM, Meitzner K, Ortega-Senovilla H, Graf K, Vetter K, Abou-Dakn M, et al. Differences in the implications of maternal lipids on fetal metabolism and growth between gestational diabetes mellitus and control pregnancies. Diabet Med. 2011;28:1053-9.
44. Schaiff WT, Barak Y, Sadovsky Y. The pleiotropic function of PPAR gamma in the placenta. Mol Cell Endocrinol. 2006;249:10-5.
45. Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, et al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci USA. 2005;102:2340-5.
46. Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest. 2006;116:581-9.
47. Suwaki N, Masuyama H, Masumoto A, Takamoto N, Hiramatsu Y. Expression and potential role of peroxisome proliferatoractivated receptor gamma in the placenta of diabetic pregnancy. Placenta. 2007;28:315-23.
48. Toth B, Hornung D, Scholz C, Djalali S, Friese K, Jeschke U. Peroxisome proliferator-activated receptors: new players in the field of reproduction. Am J Reprod Immunol. 2007;58:289-310.
49. Wadsack C, Hrzenjak A, Hammer A, Hirschmugl B, Levak-Frank S, Desoye G, et al. Trophoblast-like human choriocarcinoma cells serve as a suitable in vitro model for selective cholesteryl ester uptake from high density lipoproteins. Eur J Biochem. 2003;270:451-62.
50. Warning JC, McCracken SA, Morris JM. A balancing act: mechanisms by which the fetus avoids rejection by the maternal immune system. Reproduction. 2011;141:715-24.
51. White V, Jawerbaum A, Sinner D, Pustovrh C, Capobianco E, Gonzalez E. Oxidative stress and altered prostanoid production in the placenta of streptozotocin-induced diabetic rats. Reprod Fertil Dev. 2002;14:117-23.